Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod
Clinical Gastroenterology and Hepatology · 2025
DOI: 10.1016/j.cgh.2024.07.010 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025. Verfasst von Fernando Magro und 10 weiteren Autor:innen. Beteiligte Einrichtung: CINTESIS@RISE, Faculty of Medicine, University of Porto, Porto, Portugal. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer Inc.
Abstract (Originalsprache)
BACKGROUND & AIMS: Histologic remission, a potentially important treatment target in ulcerative colitis (UC), is associated with favorable long-term outcomes. Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active UC. This post-hoc analysis of the ELEVATE UC program evaluated the efficacy of etrasimod according to histologic and composite (histologic/endoscopic/symptomatic) endpoints and examined their prognostic value. METHODS: Patients with moderately to severely active UC were randomized 2:1 to once-daily oral etrasimod 2 mg or placebo. Histologic and composite endpoints, including disease clearance (endoscopic/histologic/symptomatic remission), were assessed at Weeks 12 (ELEVATE UC 52; ELEVATE UC 12) and 52 (ELEVATE UC 52). Logistic regressions examined associations between baseline and Week 12 histologic/composite endpoints and Week 52 outcomes. RESULTS: At Weeks 12 and 52, significant improvements with etrasimod vs placebo were observed in histologic/composite outcomes, including endoscopic improvement-histologic remission and disease clearance. The proportion of patients treated with etrasimod achieving clinical remission at Week 52 was higher among those with disease clearance at Week 12 vs those without disease clearance (73.9% [17/23] vs 28.3% [71/251]). Histologic improvement and endoscopic improvement at Week 12 were moderately and strongly associated with clinical remission at Week 52 (odds ratio [OR], 2.37; 95% confidence interval [CI], 1.27-4.41; and OR, 6.36; 95% CI, 3.47-11.64, respectively). Histologic remission and endoscopic improvement at Week 12 were strongly associated with endoscopic improvement-histologic remission at Week 52 (OR, 3.21; 95% CI, 1.70-6.06 and OR, 5.47; 95% CI, 2.89-10.36, respectively). CONCLUSIONS: Etrasimod was superior to placebo for achievement of stringent histologic and composite endpoints. CLINICALTRIALS: gov, Number: NCT03945188; ClinicalTrials.gov, Number: NCT03996369.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CINTESIS@RISE, Faculty of Medicine, University of Porto, Porto, Portugal.
- Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy, France; INSERM, NGERE, University of Lorraine, Nancy, France; INFINY Institute, Nancy University Hospital, Vandœuvre-lès-Nancy, France; FHU…
- Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
- Division of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy.
- Department of Medicine and Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
- Pfizer AG, Zürich, Switzerland.
Förderung
- Pfizer Inc
Zitieren
APA
Magro, F., Peyrin-Biroulet, L., Sands, B. E., Danese, S., Jairath, V., Goetsch, M., Bhattacharjee, A., Wu, J., Branquinho, D., Modesto, I., & Feagan, B. G. (2025). Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.07.010
Vancouver
Magro F, Peyrin-Biroulet L, Sands BE, Danese S, Jairath V, Goetsch M, et al. Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod. Clinical Gastroenterology and Hepatology. 2025. doi:10.1016/j.cgh.2024.07.010
BibTeX
@article{Magro2025,
author = {Magro, Fernando and Peyrin-Biroulet, Laurent and Sands, Bruce E and Danese, Silvio and Jairath, Vipul and Goetsch, Martina and Bhattacharjee, Abhishek and Wu, Joseph and Branquinho, Diogo and Modesto, Irene and Feagan, Brian G},
title = {Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod},
journal = {Clinical Gastroenterology and Hepatology},
year = {2025},
doi = {10.1016/j.cgh.2024.07.010}
}
EUVIMED